首页> 外文OA文献 >Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization
【2h】

Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization

机译:促肾上腺皮质激素释放因子受体2是血管生成的强音抑制剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Angiogenesis is regulated by means of a balance between activators and inhibitors. However, little is known regarding the regulation of the quiescent state of adult vessels. Corticotropin-releasing factor receptor 2 (CRFR2) is found in both endothelial and smooth muscle cells (SMCs) in the vasculature, where its function has remained elusive. We have investigated the role of CRFR2 as a determinant of tissue vascularization by comparing control and CRFR2-deficient mice with immunohistological and morphometric techniques. To define the mechanisms responsible for CRFR2 inhibition of angiogenesis, we have also examined in vitro the effect of ligand activation on cell proliferation, cell cycle protein phosphorylation, and capillary tube formation. Our results demonstrate that mice deficient for CRFR2 become hypervascularized postnatally. Activation of this receptor in vitro results in reduced vascular endothelial growth factor (VEGF) release from SMCs, an inhibition of SMC proliferation, and inhibition of capillary tube formation in collagen gels. Treatment of a subcutaneously injected gel matrix with a CRFR2 agonist inhibits growth factor-induced vascularization. Western blots show that cell cycle retinoblastoma protein, which is essential for cell cycle progression, is decreased by CRFR2 agonist treatment in SMCs. These results suggest that CRFR2 is a critical component of a pathway necessary for tonic inhibition of adult neovascularization. CRFR2 may be a potential target for therapeutic modulation of angiogenesis in cancer and ischemic cardiovascular disease.
机译:血管生成通过激活剂和抑制剂之间的平衡来调节。但是,关于成年血管静止状态的调节知之甚少。促肾上腺皮质激素释放因子受体2(CRFR2)在脉管系统的内皮细胞和平滑肌细胞(SMC)中均发现,其功能仍难以捉摸。我们已通过比较对照组和CRFR2缺陷型小鼠的免疫组织学和形态学技术,研究了CRFR2作为组织血管形成决定因素的作用。为了定义负责CRFR2抑制血管生成的机制,我们还研究了体外配体活化对细胞增殖,细胞周期蛋白磷酸化和毛细管形成的影响。我们的结果表明,缺乏CRFR2的小鼠在出生后变得血管过度。该受体的体外活化导致从SMC释放的血管内皮生长因子(VEGF)减少,抑制SMC增殖以及抑制胶原蛋白凝胶中的毛细管形成。用CRFR2激动剂对皮下注射的凝胶基质进行治疗可抑制生长因子诱导的血管生成。 Western印迹显示,SMC的CRFR2激动剂治疗可降低细胞周期视网膜母细胞瘤蛋白(对细胞周期进程至关重要)。这些结果表明,CRFR2是对成人新血管形成进行补品抑制所必需的途径的关键组成部分。 CRFR2可能是治疗性调节癌症和缺血性心血管疾病中血管生成的潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号